Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA DOI
Mazyar Shadman,

Talha Munir,

Tadeusz Robak

et al.

Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 8, 2024

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. SEQUOIA (ClinicalTrials.gov identifier: NCT03336333 ) is a phase III, randomized, open-label trial compared oral Bruton tyrosine kinase inhibitor zanubrutinib bendamustine plus rituximab (BR) treatment-naïve patients with chronic lymphocytic leukemia/small lymphoma (CLL/SLL). prespecified analysis (median follow-up, 26.2 months) and subsequent (43.7 found superior progression-free survival (PFS; point) who received BR. At median follow-up of 61.2 months, PFS was reached zanubrutinib-treated patients; 44.1 months BR-treated (hazard ratio [HR], 0.29; one-sided P = .0001). Prolonged seen versus BR mutated immunoglobulin heavy-chain variable region (IGHV) genes (HR, 0.40; .0003) unmutated IGHV 0.21 [95% CI, 0.14 0.33]; < Median overall (OS) either treatment arm; estimated 60-month OS rates were 85.8% 85.0% zanubrutinib- patients, respectively. No new safety signals detected. Adverse events as expected zanubrutinib; rate atrial fibrillation 7.1%. supported findings suggested favorable option untreated CLL/SLL.

Language: Английский

Impact of healthcare-associated infection on healthcare services and survival of patients with cancer: a propensity score-matched retrospective study DOI Creative Commons
C Y Liu, Chunhua Song, Yijie Chen

et al.

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 1, 2025

Healthcare-associated infections (HAI) lead to poor patient outcomes, including morbidity, mortality, length of hospital stay (LOS) and costs. However, limited data exists on the impact HAI LOS, cost at different quantiles survival patients with cancer. To assess HAIs costs, cancer patients. This retrospective cohort study used from January 2017 December 2018 a tertiary in Henan. Patient demographic were sourced hospital's electronic medical records. Inclusion criteria primary diagnoses (ICD codes C00-C97). We balanced distribution baseline characteristics between without using propensity score matching. Quantile regression can estimate how independent variables affect dependent quantiles. conducted quantile that assessing LOS costs for Kaplan-Meier curves compare survival. Our included 291,535 cancer, among whom 4,784(1.6%) diagnosed 286,748 not. Patients exhibited significantly longer stays, mean duration 26.1 days (range: 17.0 40.6 days), compared their counterparts HAIs, who had an average 7.2 4.0 14.0 days) (p < 0.01). Economically, hospitalization was $1575.8 865.6 3106.3), substantially lower than $8710.8 $4073.8 13434.0) observed After adjusting confounders models, associated median increase 11.4 (95% confidence interval (CI): 10.9-12.0) excess USD 3449.3 CI: 3281.9-3616.7). The hazard ratio (HR) death higher (HR: 1.62, 95% 1.50-1.74). prolongs increases worsens other diseases. results indicate is more pronounced (e.g., 95th percentile). suggests severe conditions or advanced disease stages are vulnerable adverse effects HAI. Targeted surveillance preventive interventions, such as early infection screening strict adherence control protocols, should focus high-risk prolonged high By preventing these patients, we effectively reduce additional burden LOS. informs clinical practice decision-making nurses nursing educators manage healthcare professionals helped collection Hospital.

Language: Английский

Citations

0
Critical roles of chronic BCR signaling in the differentiation of anergic B cells into age-associated B cells in aging and autoimmunity DOI Creative Commons
Keisuke Imabayashi, Yutaro Yada, Kazuhiko Kawata

et al.

Science Advances, Journal Year: 2025, Volume and Issue: 11(16)

Published: April 18, 2025

Age-associated B cells (ABCs) with autoreactive properties accumulate age and expand prematurely in autoimmune diseases. However, the mechanisms behind ABC generation maintenance remain poorly understood. We show that continuous cell receptor (BCR) signaling is essential for development from anergic aged mice. ABCs exhibit constitutive BCR activation, surface BCRs being internalized. Notably, cells, but not nonautoreactive contributed to formation these models. Anergic also showed a greater propensity vitro differentiation into ABCs, which was inhibited by expression of transcription factor Nr4a1. Bruton’s tyrosine kinase (Btk), key component, constitutively activated mice as well patients lupus. Inhibiting Btk reduced numbers ameliorated pathogenicity lupus Our findings reveal critical underlying offer previously unrecognized therapeutic insights

Language: Английский

Citations

0
Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors DOI
Francesca Romana Mauro, Anna Maria Frustaci, Andrea Visentin

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 201, P. 104408 - 104408

Published: June 15, 2024

Language: Английский

Citations

1
Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG) DOI Open Access
Elżbieta Kalicińska, Paula Jabłonowska, Marta Morawska

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4168 - 4168

Published: Dec. 13, 2024

Background/Objectives: Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections that can affect their clinical outcomes. Aims: The aims of this study were assess the following: (1) incidence pneumonia in CLL patients treated venetoclax-based regimens a real-world setting, (2) risk factors for event-free survival (EFS), and (3) overall (OS). Methods: This multicenter included 322 from eight centers. Univariable multivariable analyses (MVA) performed, development during treatment OS as Results: most common complication was neutropenia (59%). During regimens, 66 (20%) developed pneumonia—50 (23%) rituximab-plus-venetoclax (R-VEN) group 13 (16%) obinutuzumab-plus-venetoclax (O-VEN) (p = 0.15). Chronic obstructive pulmonary disease (COPD)/asthma, splenomegaly, elevated creatinine, anemia < 8 g/dL EFS MVA (HR 2.08, 95%CI 1.16–3.74, p 0.014; HR 1.73, 1.08–2.78, 0.02; 2.13, 1.10–4.11, 0.03, 3.58, 2.18–5.89, 0.001, respectively). Relapsed/refractory (R/R) R-VEN had worse than those without 0.001). In O-VEN, median did not differ between 0.45). Conclusions: Our showed venetoclax occurs more frequently reported registration trials has negative impact on OS, especially R/R who R-VEN. Neutropenia is factor pneumonia.

Language: Английский

Citations

1
Management of infections for patient treated with ibrutinib in clinical practice DOI Creative Commons
Claudia Baratè,

Ilaria Scortechini,

Sara Ciofini

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Sept. 10, 2024

Ibrutinib, a highly effective inhibitor of the Bruton tyrosine kinase, has significantly transformed therapeutic approach in chronic lymphocytic leukemia (CLL). Despite these advancements, disease continues to be characterized by immune dysfunction and increased susceptibility infections, with mortality rates from infections showing no significant improvement over past few decades. Therefore, timely prevention, recognition, treatment remains an important aspect standard management patient CLL. A panel hematologists expertise CLL met discuss existing literature clinical insights for infectious undergoing ibrutinib treatment. not being fully comprehensive review on topic, this work provides set practical recommendations that can serve as guide healthcare professionals who manage patients their daily practice.

Language: Английский

Citations

0
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA DOI
Mazyar Shadman,

Talha Munir,

Tadeusz Robak

et al.

Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 8, 2024

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. SEQUOIA (ClinicalTrials.gov identifier: NCT03336333 ) is a phase III, randomized, open-label trial compared oral Bruton tyrosine kinase inhibitor zanubrutinib bendamustine plus rituximab (BR) treatment-naïve patients with chronic lymphocytic leukemia/small lymphoma (CLL/SLL). prespecified analysis (median follow-up, 26.2 months) and subsequent (43.7 found superior progression-free survival (PFS; point) who received BR. At median follow-up of 61.2 months, PFS was reached zanubrutinib-treated patients; 44.1 months BR-treated (hazard ratio [HR], 0.29; one-sided P = .0001). Prolonged seen versus BR mutated immunoglobulin heavy-chain variable region (IGHV) genes (HR, 0.40; .0003) unmutated IGHV 0.21 [95% CI, 0.14 0.33]; < Median overall (OS) either treatment arm; estimated 60-month OS rates were 85.8% 85.0% zanubrutinib- patients, respectively. No new safety signals detected. Adverse events as expected zanubrutinib; rate atrial fibrillation 7.1%. supported findings suggested favorable option untreated CLL/SLL.

Language: Английский

Citations

0